Login to Your Account



AUSTIN, Texas – Roswell Park Cancer Center is about to form a 50:50 joint venture (JV) with Cuba's Center for Molecular Immunology (CIM) to commercialize cancer vaccines developed by CIM.

At the WORLD Symposium on lysosomal diseases in San Diego this month, Ultragenyx Pharmaceutical Inc. made a splash with data related to Mepsevii (vestronidase alfa-vjbk, previously UX-003), the company's first drug to win approval.

FDA experts are teaming up with patients to help drug developers explore one of the final frontiers in the human body as they seek new cures and therapies for neurological diseases.

More Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: